DASISION
DASISION showed that the second-generation drug dasatinib brought chronic myeloid leukaemia under control faster and more deeply than imatinib when used from diagnosis, though after five years patients lived equally long on either.
Overview
DASISION randomised 519 patients with newly diagnosed chronic-phase chronic myeloid leukaemia to dasatinib 100 mg once daily or imatinib 400 mg once daily. The primary endpoint was confirmed complete cytogenetic response by 12 months.
Dasatinib produced higher rates of complete cytogenetic and major molecular response at 12 months, and responses came sooner, which led to its first-line approval in 2010. With five years of follow-up the rates of progression to advanced phase were lower with dasatinib, but overall survival was the same in both arms, and pleural effusions were commoner with dasatinib. Together with ENESTnd (nilotinib) and BFORE (bosutinib), it established that second-generation inhibitors give faster, deeper responses without a survival advantage, which is why imatinib remains a reasonable first choice for many patients.
Similar pages
not linked directly; found by shared links- TrialATTRACTION-2
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialCheckMate 915
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialMEDALIST
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialCheckMate 025
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialCheckMate 227
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialAZA-001
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialCOMMANDS
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialCheckMate 358
Shares Bristol Myers Squibb and the tag subtype-trials.